Included in the formulation
АТХ:R.07.A.B Respiratory stimulants
Pharmacodynamics:Provides analeptic, anti-inflammatory, anti-allergic action. Excites the center of the brain's medulla oblongata, increases its sensitivity to humoral stimuli and nerve impulses, increases the frequency and amplitude of respiratory movements. Increases blood pressure, improves short-term memory and mental efficiency. Increases the excitability of the vasomotor center, renders moderate myotropic spasmolytic action, stimulates skeletal muscles. Oppresses the cerebral cortex, eliminating the state of anxiety.
Pharmacokinetics:Well absorbed with different routes of administration. Easily passes through gistogematicheskie barriers, including the blood-brain barrier. The liver undergoes biotransformation. It is excreted by the kidneys.
Indications:Stimulation of breathing: poisoning with drugs and analgesics, carbon monoxide, surgical anesthesia, hypoventilation of lungs with atelectasis, asphyxia, post-fixation states and respiratory distress in newborns.
As an anti-inflammatory (arthritis, polyarthritis) and bronchodilator (bronchial asthma of the lung and obstructive bronchitis), asthenic conditions.
X.J40-J47.J44 Other chronic obstructive pulmonary disease
X.J40-J47.J45 Asthma
XVI.P20-P29.P21 Asphyxia in childbirth
XVI.P20-P29.P22 Breathing disorder in a newborn [distress]
XVIII.R50-R69.R55 Fainting [syncope] and collapse
XIX.T51-T65.T58 Toxic effect of carbon monoxide
Contraindications:Individual intolerance.
Severe CNS depression.
Motor and mental arousal.
Insomnia.
Poisoning with convulsive poisons.
Arterial hypertension.
Glaucoma.
Severe forms of atherosclerosis.
Decompensated diseases of the cardiovascular system.
Elderly age.
Carefully:Epilepsy and cramps in the anamnesis.
Conditions accompanied by hypoxia of the brain.
Porphyria.
Edema of the brain.
Head injury.
Severe asthma.
Obstruction of the respiratory tract.
Cardiac ischemia.
Hyperthyroidism and pheochromocytoma.
Pregnancy and lactation: The category of FDA recommendations is not defined. Not recommended during pregnancy and during breastfeeding.
Dosing and Administration:Stimulation of the respiratory center - intravenously (slowly), intramuscularly, subcutaneously at 0.6-1 mg / kg 1-2 times a day 1.5% solution.
Prenatal prevention of respiratory distress of newborns -women with a threat of termination of pregnancy at the period of 28-35 weeks: for 6-7 days intravenously drip 1 time per day 2 ml of a 1.5% solution in 200 ml of 0.9% sodium chloride solution or inside by 0.025 g (1/4 tablets) 2 times a day.
To maintain the stimulating effect of glucocorticoids on the synthesis of surfactant in preterm infants, intramuscularly at 0.2-1 mg / kg 1-3 times a day for 2-3 days.
As a bronchodilator for chronic obstructive pulmonary disease, bronchial asthma, intramuscularly 2 ml of a 1.5% solution 2 times a day or inward 0.1 g 3-4 times a day.
As an anti-inflammatory drug - inside (after eating) 0.1 g 3-4 times a day for arthritis, polyarthritis. The course of treatment is 20-30 days.
Side effects:Respiratory system: dyspnea, cough, broncho- and laryngospasm, hiccough, hyperventilation, "ricochet" hypoventilation.
Nervous system: anxiety, muscle twitching (beginning with the circular muscles of the mouth).
Leather: redness of the skin of the face, itching of the skin.
Others: vomiting, arrhythmias, infiltration and soreness at the injection site.
Allergic reactions.
Overdose:When an overdose develops anxiety, irritability, headache, insomnia, tachypnea, tachycardia, tremor, reflex intensification, clonic convulsions. Treatment is symptomatic.
Interaction:Narcotic analgesics, hypnotics, antipsychotic drugs, anxiolytics, anticonvulsants - reducing their effect.
Para-aminosalicylic acid, phenothiazine derivatives and anesthetic agents - a decrease in the effect of ethylimidazole dicarbonate methylamide.
Psychostimulants, antidepressants - enhancing their effect.
Reserpine - increased likelihood of seizures.
Theophylline - increased half-life theophylline.
Cimetidine is a slowing down of the metabolism of ethylimidazole dicarbonate methylamide and an increase in its concentration in the blood.
Special instructions:No data.